Clinical Research Directory

Inclusion Criteria: * Aged 18-80 years * In good general health, (at least ASA 2) * Previously treated implants must have probing depths (PD) ≤ 4 mm * Previously treated implants must have \<50% bone loss around the implant of interest (assessed radiographically) * Patients must have been treated previously for peri-implantitis with or without IP, with at least 1 thread or 2 mm of implant surface exposed in the oral cavity. * Have little to no bacteria on the implant(s) of interest (modified Plaque Index of \<1) by Day 0 * Have healthy gums that do not bleed around the implant(s) of choice (modified Gingival index \<1) by Day 0 * Have evidence of stable bone levels around the treated implant for \> 6 months Exclusion Criteria: * Active infectious diseases of any kind. * Medical conditions which require premedication prior to dental treatments/visits. * Pregnant women or planning to become pregnant (self-reported). * Patients with congenital or metabolic bone disorders (ie. osteoporosis, vitamin D deficiency, parathyroid disease, etc.) * Current heavy smokers: Subjects who have smoked more than 1 pack/day within 6 months of study onset (self-reported) * Subjects with co-morbid conditions (i.e., uncontrolled diabetes, cardiovascular disease, impaired kidney function, heart murmur, rheumatic fever, bleeding disorder, hepatitis, tuberculosis, HIV) that would affect the study outcome or interpretation of study results will be excluded. * Concomitant medications: Subjects on significant concomitant drug therapy for systemic conditions (i.e., Chronic anti-inflammatory medication, antibiotics, anticoagulants, any medication initiated \<3 months prior to the screening visit) will not be included in the study. Occasional short-term use (7-14 days) of analgesics or common cold medication is permitted. Such use of these medications will be reviewed and recorded by the Investigator.